Viral infection, Human immunodeficiency virus
IMCRImmunocore HoldingsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for IMC-M113V (Gag-A02) in Viral infection, Human immunodeficiency virus. The expected timing is based on the latest available company guidance and may change.
STRIVE Trial. 2/22/23- Presented safety and activity data at CROI 2023. Plans to enroll more PLWH to characterize anti-viral activity & Data in Q1 2025. 3/11/25- Initial MAD data reported at CROI 2025. 11/06/25:- STRIVE Ph1/2 MAD cohorts now enrolling higher doses to define a safe and tolerable regimen in PLWH. 02/25/26:- STRIVE Phase 1/2 MAD HIV trial continues dose escalation; additional Phase 1 data planned for presentation in H2 2026. 05/06/26:- STRIVE Ph1/2 MAD HIV trial enrolling higher doses; additional Phase 1 MAD data expected H2 2026. 08/06/26:- STRIVE MAD higher-dose enrollment completed; new results planned Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.